Top Story

Ibrutinib dose adherence associated with higher PFS for CLL

May 4, 2016

Taking ibrutinib at full dose and on schedule improved PFS among patients with chronic lymphocytic leukemia, according to an analysis of the RESONATE trial presented at the Oncology Nursing Society Annual Congress.

“Patients who missed 8 or more consecutive days of ibrutinib oral chemotherapy experienced a higher rate of progression events as opposed to those patients who did not have a drug hold for longer than 1 week," Sarah Deisinger, RN, BSN, told HemOnc Today. “What we can take away from this study, as providers, nurses and other medical professionals, is the critical importance of educating outpatients on oral drug adherence. This includes the ability to be transparent with our patients in regard to treatment outcomes for drug holds greater than 8 days, as well as the effect on PFS.”

FDA News

FDA grants priority review to olaratumab for soft tissue sarcoma

May 4, 2016
The FDA granted priority review for olaratumab in combination with doxorubicin to treat patients with advanced soft tissue sarcoma who are not responsive to curative…
FDA News

FDA grants priority review to Blinctyo to treat pediatric B-cell precursor ALL

May 4, 2016
The FDA granted priority review to blinatumomab for the treatment of pediatric and adolescent patients with Philadelphia chromosomenegative relapsed or refractory B-cell…
In the Journals

Chemoradiotherapy does not prolong OS in locally advanced pancreatic cancer

May 4, 2016
The addition of radiation to chemotherapy failed to improve OS for patients with locally advanced pancreatic cancer, according to the results of the randomized…
In the Journals

Zoledronic acid reduces skeletal complications for men with progressive bony prostate cancer

May 3, 2016
The addition of zoledronic acid to docetaxel significantly reduced the rate of skeletal-related events but did not prolong OS or clinical PFS among men with metastatic…
More News Headlines »

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Meeting News Coverage

VIDEO: CAR-T cell therapy may target EGFR variant III in glioblastoma

April 26, 2016
More »
CME Video

World Lung Updates: Immunotherapy in NSCLC

This activity is supported by an educational grant from Genentech, Inc and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Current Issues
View the Current Issue
HemOnc Today